Great opportunities with a new international laboratory partner: Abomics and German LADR begin co-operation

Great opportunities with a new international laboratory partner: Abomics and German LADR begin co-operation

Digital Health
Diagnostics
Clinical Research
Healthcare
Articles
News
Research

Abomics has successfully been seeking for international partners, the newest one being a significant and highly advanced European laboratory network LADR Der Laborverbund Dr. Kramer & Kollegen.

LADR has a strong history that dates back to over 70 years. This well-established medical laboratory has expanded their market share and increased their highly academic knowledge over the decades. The family company in generations is a true example of continuity and family legacy. The original Dr. Kramer family is still in charge of LADR, together with three additional doctors as owners and medical directors.

Abomics is thrilled to announce this co-operation with the major laboratory network that receives over 5 million requests annually. This partnership creates significant international contacts and opens new possibilities in expanding the global market share as LADR works with over 370 hospitals. Seeing that the German markets are truly attractive, Abomics will nurse this partnership with highpriority.

LADR has over 3,000 employees and also have a long-term laboratory partner Vita Oy in Finland. As the collaboration with Finland already exists, it is a natural move to start utilizing Abomics’ pharmacogenetic expertise.

Abomics is looking forward to all the new opportunities and increased revenue this collaboration will bring to both companies involved. The partnership is already validated and the first pharmacogenetic samples will be delivered within August, 2018.

 

Further Information:

www.abomics.fi
www.geneaccount.com
CEO Jari Forsström, Abomics Ltd
+358 (0)40 544 1809, jari.forsstrom@abomics.fi
 


Related posts